APA (7th ed.) Citation

Ye, Y., Park, J., Kim, S., Cho, Y. S., Lee, S. Y., Lee, S. Y., . . . Park, H. (2024). Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study. International immunopharmacology, 130, 111706. https://doi.org/10.1016/j.intimp.2024.111706

Chicago Style (17th ed.) Citation

Ye, Young-Min, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of YH35324, a Novel Long-Acting High-Affinity IgETrap-Fc Protein in Subjects with Atopy: Results from the First-in-Human Study." International Immunopharmacology 130 (2024): 111706. https://doi.org/10.1016/j.intimp.2024.111706.

MLA (9th ed.) Citation

Ye, Young-Min, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of YH35324, a Novel Long-Acting High-Affinity IgETrap-Fc Protein in Subjects with Atopy: Results from the First-in-Human Study." International Immunopharmacology, vol. 130, 2024, p. 111706, https://doi.org/10.1016/j.intimp.2024.111706.